SYNTHETIC IGE PEPTIDE VACCINE FOR IMMUNOTHERAPY OF ALLERGY

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。该实验将在相关动物模型（狒狒）中检验UBI治疗过敏的疗效。UBI过敏治疗含有一片免疫球蛋白E （IgE）抗体。[IgE抗体是对抗过敏原的抗体，引起大多数过敏反应。UBI治疗中的IgE片段是通过化学合成产生的，并已与各种疫苗成分结合。因此，UBI疗法被设计成一种疫苗，可以引发针对个体自身IgE的保护性抗体。因此，疫苗会中和任何IgE引起过敏反应的能力。这种治疗性抗IgE免疫反应仅针对靶向IgE片段，而对正常抗体没有作用。这种用IgE疫苗治疗过敏的方法还有一个额外的优点，那就是它将对所有IgE介导的过敏有效治疗，而不需要识别或针对特定的过敏原（如树和草花粉、动物皮屑、尘螨等）进行定制治疗。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The experiment will examine the efficacy of UBI¿s therapy for allergy in a relevant animal model (baboons). The UBI allergy therapeutic contains a piece of Immunoglobulin E (IgE) antibody. [IgE antibodies are the antibodies that react against allergens and cause most allergic reactions.] The piece of IgE in the UBI therapy was produced by chemical synthesis and has been combined with various vaccine components. Therefore the UBI therapy has been designed to act as a vaccine that elicits protective antibodies against the individual¿s own IgE. Accordingly, the vaccine will neutralize the ability of any IgE to cause allergic reactions. This therapeutic anti-IgE immune response is specifically directed against only the targeted piece of IgE, while having no effect on normal antibodies. This IgE vaccine approach to allergy therapy has the additional advantage that it will be effective therapy for all IgE-mediated allergies with no need to identify or tailor treatment for specific allergens such as tree and grass pollens, animal danders, dust mites, etc.